Cassava Sciences Announces Conference Call for Second Quarter Financial Results
- Call-in on Tuesday, August 3rd at 9 a.m. ET -
Get Alerts SAVA Hot Sheet
Join SI Premium – FREE
AUSTIN, Texas, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, will release financial results for the period ending June 30, 2021 on Tuesday, August 3, 2021 before the market opens, followed by a conference call.
Remi Barbier, President & CEO, and Eric Schoen, Chief Financial Officer, will host a conference call to review financial results and to preview the Company’s growth strategy.
The conference call is scheduled to begin at 9:00 am ET on Tuesday, August 3, 2021. Please dial in 15 minutes in advance to ensure a timely connection to the call.
Conference call detail are as follows: | ||
Toll Free: | 1-888-254-3590 | |
Toll/International: | 1-323-794-2575 |
After the live call, the event will be archived on the ‘Investors’ page of the Company’s website: https://www.CassavaSciences.com.
Live Event Click to Join Link (for participant entry):
https://event.mymeetingroom.com/Public/ClickToJoin/ZW5jPXZYWEV4Yks0aWhyTWp1ZnBWOTF1Zk5zaHl1NW5jVGVodEtGUTJ0WFZJNjREdWd1VUZYY0drdz09 | |
| |
|
About Alzheimer’s DiseaseAlzheimer’s disease is a progressive brain disorder that destroys memory and thinking skills. As of 2020, there were approximately 50 million people worldwide living with dementia, a figure expected to increase to 150 million by 2050.1 The annual global cost of dementia is now above $1 trillion, according to Alzheimer’s Disease International, a charitable organization.
About Cassava Sciences, Inc.Cassava Sciences’ mission is to discover and develop innovations for chronic, neurodegenerative conditions. Over the past 10 years, Cassava Sciences has combined state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimer’s disease. For more information, please visit: https://www.CassavaSciences.com.
For More Information Contact:Eric Schoen, Chief Financial Officer[email protected](512) 501-2450
For information regarding risks related to our business, investors please consult our filings with the SEC, which are available on the SEC's website at www.sec.gov.
1 Alzheimer's Disease International, Dementia Statistics, available on-line.
Source: Cassava Sciences, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- Nanometrics (NANO) Issues Business Update, Reports FY23 Results
- IBM (IBM) to Acquire HashiCorp (HCP) for $35/sh Cash or $6.4B
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!